Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of “Hold” from Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has earned a consensus recommendation of “Hold” from the twenty-three analysts that are currently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $20.25.

NTLA has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their price objective on Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a report on Tuesday, April 28th. Citizens Jmp lifted their price objective on Intellia Therapeutics from $28.00 to $30.00 and gave the company a “market outperform” rating in a report on Tuesday, April 28th. Bank of America reaffirmed a “neutral” rating on shares of Intellia Therapeutics in a report on Monday, March 2nd. Robert W. Baird lifted their price objective on Intellia Therapeutics from $7.00 to $13.00 and gave the company a “neutral” rating in a report on Monday, April 27th. Finally, JonesTrading upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a research note on Wednesday, March 4th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Bank of America Corp DE raised its stake in shares of Intellia Therapeutics by 11.2% in the first quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock valued at $17,713,000 after acquiring an additional 139,325 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Intellia Therapeutics in the first quarter valued at approximately $250,000. California State Teachers Retirement System raised its stake in shares of Intellia Therapeutics by 39.6% in the first quarter. California State Teachers Retirement System now owns 138,259 shares of the company’s stock valued at $1,772,000 after acquiring an additional 39,253 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Intellia Therapeutics by 1,082.1% in the first quarter. Royal Bank of Canada now owns 465,499 shares of the company’s stock valued at $5,968,000 after acquiring an additional 426,121 shares during the last quarter. Finally, Quantinno Capital Management LP raised its stake in shares of Intellia Therapeutics by 18.7% in the first quarter. Quantinno Capital Management LP now owns 39,709 shares of the company’s stock valued at $509,000 after acquiring an additional 6,266 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $11.94 on Wednesday. The firm has a 50-day simple moving average of $13.59 and a 200 day simple moving average of $11.95. Intellia Therapeutics has a twelve month low of $6.83 and a twelve month high of $28.25. The stock has a market cap of $1.67 billion, a PE ratio of -3.37 and a beta of 1.93.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.11. The business had revenue of $15.05 million during the quarter, compared to analysts’ expectations of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same quarter last year, the company earned ($1.10) earnings per share. Research analysts forecast that Intellia Therapeutics will post -3.35 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.